In fact, a study has shown that tumors quickly overcame immune responses by inhibiting the function of CD8 and CD4 T cells, driving a shift to a higher Treg/Teff ratio and upregulating PD-L1/PD-1 expression, which result suggested that tumor microenvironment after hyperthermia is variable and is favorable for anti-PD-1/PD-L1mAb treatment for only a narrow time window (105). This evidence concerns the gene CD8A and neoplasm.